BIO 2024 Sessions | June 3-6 | San Diego

At BIO 2024, where issues & insights converge, you can access more than 100 sessions across 18 focus areas with discussions from leading biotechnology companies, investors, service providers, government officials, regulators, and patient advocates committed to ground-breaking therapies and innovation.

Be sure to register for a Premier Access or General Access pass in order to attend these sessions.

Follow this schedule for updates as new speakers and topics become available.

Loading

Company Presentations

Company Presentation

Partnering with the U.S. Government to Achieve Our National Security Mission
Breakout Session
- Infectious Disease and Vaccines
30ABCDE

How to Build a Successful and Competitive Biopharma Ecosystem in Southeast Asia
Special Program
- Emerging Opportunities in Global Markets
28ABCDE
Mai Zymaris, Counsel - Baker McKenzie

Mr. Phong Tran, CEO - BOUND Therapeutics and siRnaMed Therapeutics

John Mattison, Operating Partner and Chief Medical Information Officer - Arsenal Capital Partners

Anh Hoang-Lindsay, CEO - Jana Care

A Discussion on Increasing Healthspan
Breakout Session
- Next Generation Biotherapeutics
23BC
Hilary Brueck, Journalist - Business Insider

Mr. Dan Oliver, CEO & Co-Founder - Rejuvenate Bio

Katharine Grabek, Co-Founder and CSO - Fauna Bio

Mike Curtis, CEO - eGenesis

Jake Becraft, CEO & Founder - Strand Therapeutics

Alex Aravanis, CEO - Moonwalk Biosciences
A Licensing Deal for All Seasons
Breakout Session
- Business Development and Finance
29AB
Jonathan Grinstein, Senior Editor - Genetic Engineering & Biotechnology News

Uneek Mehra, CHIEF FINANCIAL & BUSINESS OFFICER - 4DMT

Mr. Kunal Patel, VP of Business Development - Synthekine

Dr. Gavin Samuels, Chief Business Officer - CinRx Pharma
All Money is NOT Created Equal: The Differences between Angel, Venture and Strategic Capital in the Biotech Funding Ecosystem
Breakout Session
- Business Development and Finance
32AB
Mr. Yaniv Sneor, Founder & Managing Director - Mid Atlantic Bio Angels

Jonathan McClain, Executive Director, Eli Lilly Catalyze team - Eli Lilly

Dr. Max Farina, Senior Associate - 5AM Ventures
Alternative Funding Programs: Protecting Patients in an Ever-Changing Healthcare Landscape
Breakout Session
- Patient Advocacy
26A
Ashira Vantrees, Counsel - Aimed Alliance

Kollet Koulianos, Vice President Payer Relations - National Hemophilia Foundation

Kim Czubaruk, Associate Vice President of Policy - Cancer Care

Richard Meyers, Head, State Policy - Bristol Myers Squibb

Dani Peters, President - Magnet Strategy Group
Building Capacities in the Industry for Secondary Uses of Health Data: The EHDS Framework
Breakout Session
- AI and Digital Health
24BC
Dr. Montse Daban, Director of Strategic Foresight and International Relations and President - Biocat and The Council of European BioRegions

Dr. Jean Marc Bourez, CEO - EIT Heatlth

Ms. Elina Drakvik, Senior lead, Health Data 2030 - Sitra

Sinéad O'Connor, Adjunct Ass. Professor, School of Medicine - Trinity College
Empowering Real World Patient-Centric Digital Health in Asia with Digital Apps
Breakout Session
- AI and Digital Health
28ABCDE
Dr. Tsu-Hui Liu, Director of Biotechnology, Health, Medicine and Agriculture Division, - Office of Science and Technology Policy, National Science and Technology Council (NSTC)

Dr. Jared Josleyn, Global Head of Digital Healthcare - Sanofi

Mr. Chu-Yie Deng, co-founder and CEO - Health2Sync

Dr. Allen Lien, Chairman & CEO - Acer Medical Inc.
Super Session

Fireside Chat with Nauman Shah, Global Head, Janssen Business Development, Johnson & Johnson

Super Session 30ABCDE

Sponsored by:

Nauman Shah, Global Head, Janssen Business Development - Johnson & Johnson
Lessons from the Oregon Trail: Pioneering Gene Therapy in the Real World
Breakout Session
- Cell and Gene Therapy and Genome Editing
31AB
Tom Klima, Chief Operating and Commercial Officer - bluebird bio

Mr. Joe Garrity, Senior Director, Head of Autologous Cell Therapy - Lonza

Tim Olson, Medical Director, Blood and Marrow Transplant Program - Children's Hospital of Philadelphia

Michelle Campbell, Caregiver - N/A

Kirk Davis, Clinical Business Program Manager, Gene Therapy - Cigna
The Cross-Border Applicability of RWD in Decision-Making
Breakout Session
- Regulatory Innovation
31C
Emily Casey, Founder and Director - What the Health

Dario Heymann, Chief Growth Officer - Galen Growth

Edmund Zhou, Director, Innovation and Enterprise - Ministry of Health, Singapore

Matthew Howard, Head Healthcare AI, GenAI and Data Sciences | International Healthcare Strategy lead - Amazon

Rachel Ehlers, Partner - Baker McKenzie
The Time is Now: Global Perspectives on Preparing for Public Health Emergencies
Breakout Session
- Infectious Disease and Vaccines
29C
Sponsored by:

A New Era for Access and Affordability: Considerations for Patients and Manufacturers in a Post-IRA World
Breakout Session
- Patient Advocacy
26A
Mark Gooding, Managing Director - Avalere
A Perspective from the Trenches: Challenges of Budgeting for Gene Therapies, Innovative Payment Systems That Work for Medicaid Departments and Patients, and What the States Need from CMS
Breakout Session
- Cell and Gene Therapy and Genome Editing
31AB
Thomas Barker, Partner - Foley Hoag LLP

Paul Jeffrey, Former Senior Director of Pharmacy - MassHealth

Scott McGoohan, Executive Director, Policy and Alliance Development - Vertex Pharmaceuticals

Mr. Jay Newman, SVP, Commercial Development, Pricing & Reimbursement - Spark Therapeutics, Inc.
AI and Regulatory Innovation in Healthcare: Shaping the Future
Breakout Session
- Regulatory Innovation
31C
Paul Howard, Senior Director of Public Policy - Amicus Therapeutics

Lina Nilsson, VP of Product - Recursion

Meredith Brown-Tuttle, Chief Regulatory Strategist - Regulatorium

Shlomo Klapper, COO - Weave
An Insider Look at Top Deals from 2023
Breakout Session
- Business Development and Finance
29AB
Carin Canale-Theakston, CEO - Evoke Canale

Mark McKenna, CEO - Mirador Therapeutics

Enoch Kariuki, President - Endeavor Biomedicines
Biotech Beyond Borders: Emerging Stronger from a Complex Macroenvironment
Breakout Session
- Business Development and Finance
32AB
Mr. Arda Ural, Americas Leader for Life Sciences and Healthcare - EY (Ernst & Young)

Mr. Chris Garabedian, CEO - Xontogeny

Ms. Barbara Ryan, Board Member - Indivior, Mink, OccuTerra, Invo, SafeCor Pharmaceutical Companies

Brian Bronk, Global Head of Business Development, Neurology, Rare Diseases & Technology Platforms - Sanofi
Emerging Technologies Fostering Biotech Innovation Globally
Breakout Session
- Emerging Opportunities in Global Markets
26B
Dr. Falk Ehmann, Head of Innovation and Development Accelerator (IDeA) - European Medicines Agency (EMA)

Dr. Blythe Adamson, Senior Principal Scientist, Head of Outcomes Research - Flatiron Health

Lesley Maloney, Global Regulatory Policy Lead for Digital Health - Genentech, Inc., A Member of the Roche Group

Irene Norstedt, Director, DG Research and Innovation - European Commission

Vivek Thakkar - Biologics Consulting
Fireside Chat

Fireside Chat with Stephen Quake, Head of Science, Chan Zuckerberg Initiative

Fireside Chat

Steve Quake, Head of Science - Chan Zuckerberg Initiative
Forging New Pathways to Reimbursement for Digital Therapeutics: Considerations for Payer Coverage
Breakout Session
- AI and Digital Health
24BC
Brigit Kyei-Baffour, Principal - Avalere

Mona Chitre

Jon Campbell
Global Policy Perspectives on the Next Generation of Rare Disease Medicines
Breakout Session
- Orphan and Rare Disease
25ABC
Sponsored by:

Jannie Oosthuizen, President - Merck
Let’s Go STEDI: Moving Beyond QALY’s to Understand the True Value of Antimicrobials and Vaccines
Breakout Session
- Infectious Disease and Vaccines
29C
Dr. Ted Buckley, Vice President, Government Affairs - Shionogi

Dr. John Rex, Chief Medical Officer - F2G

Dr. Scott Johnson, CEO/Founder - Medicus Economics

Ms. Ella Balasa, Patient Expert - Balasa Consulting
Longevity Therapeutics Enter Biopharma Mainstream
Breakout Session
- Next Generation Biotherapeutics
23BC
Brian Gormley, Reporter - Wall Street Journal

Dr. Marco Quarta, Founder and CEO - Rubedo Life Sciences

Robert Gould, Operating Partner - Khosla Ventures

Dr. Simone Fantaccini, Chief Scientific Officer & Head of Medical Affairs - Novartis

Cristina Ghenoiu, Investor - Mubadala Capital

Hanadie Yousef, Chief Executive Officer and Co-Founder - Juvena Therapeutics
Patients Wait Less: Streamlining Regulatory Pathways for Cell/Gene Therapies in Asia-Pacific Region
Special Program
- Cell and Gene Therapy and Genome Editing
28ABCDE
Dr. Pi-Sheng Wang, Deputy Minister - Ministry of Health and Welfare

Akira Sakurai, Deputy Reviewer Director - Pharmaceuticals and Medical Devices Agency

Dr. Yueh-Ping Liu, Director-General - Department of Medical Affairs, Ministry of Health and Welfare

Dr. Maggie Ho, General Manager, Asian Business & CMC Regulatory Development - Amarex Clinical Research, LLC

Mr. Joseph Damond, Chair of Health Policy - Edelman Global Advisory

Agile Biologics Manufacturing Strategy to Meet Market Demand

Breakout Session

Sponsored by:
Altering the Regulatory Ecosystem for Pediatric Clinical Programs: Intended and Unintended Consequences
Breakout Session
- Regulatory Innovation
31C
Dr. Catherine Lee, Associate Director, Global Regulatory Policy and Intelligence - Johnson & Johnson

Dr. Laurie Conklin, Senior Director, Pediatric Development - Johnson & Johnson

Dr. Dionna Green, Director, Office of Pediatric Therapeutics - FDA

Dr. Thomas Miller, Global Head, Acute, Chronic & Pediatric Disease Nucleus - Bayer
Avoid the Cycle of “Panic and Neglect": How Ongoing Commitment to Innovative Partnerships Futureproofs Against the Next Pandemic
Breakout Session
- Infectious Disease and Vaccines
29C
Paul Friedrichs, Director - Office of Pandemic Preparedness and Response Policy (OPPR)

Dr. Georges Benjamin, Executive Director - American Public Health Association

Dr. Robert Walker, Senior Vice President and Chief Medical Officer - Novavax, Inc.

Mr. Laurent Muschel, Director - Deputy Head - European Commission, Health Emergency Preparedness and Response Authority (HERA)
Creative Structures for Keeping Innovation Alive After the Deal
Breakout Session
- Business Development and Finance
29AB
Mr. Oren Livne, Partner - Baker McKenzie

Gavin Liu, Senior Director, Legal Strategic Transactions - Astellas

Dr. Paul van der Horst, Chief Business Officer - AgomAb Therapeutics

Deepa Talpade, Vice President, Head BD&L and Alliance Mgmt., Oncology - Bayer
Fireside Chat

Fireside Chat with Matt Gline, CEO, Roivant Sciences

Fireside Chat 30ABCDE

Michelle Davis, M&A Reporter - Bloomberg News

Matt Gline, Chief Executive Officer - Roivant Sciences
From Patients to Partners: Patient Advocacy and Biotech Collaborate to Accelerate Innovation
Breakout Session
- Patient Advocacy
26A
Anthony Mancini, EVP & Chief Operating Officer - Genmab

Meghan Gutierrez, CEO - Lymphoma Research Foundation

Portia Badham
Gun Violence Prevention: A Case Study in Passing Meaningful Policies in a Hyper Partisan Era

Special Program 25ABC

Josh Horwitz, Co-director - Johns Hopkins Center for Gun Violence Solutions

Angus McQuilken, Life Sciences Industry Relationship Executive - McDermott Will & Emery

Jen Pauliukonis, Director of Policy and Programming - Johns Hopkins Center for Gun Violence Solutions

Traci Murphy, Executive Director - Coalition for a Safer Delaware
Innovation Passport: Emerging Opportunities for Company Growth in Global Markets
Breakout Session
- Business Development and Finance
32AB
Ms. Susie Harborth, Chief Business Officer - Breakthrough Properties

Bernard Parker, Chief Business Officer - Shanghai Pharma Biotherapeutics USA, Inc.

Dr. Avi Spier, Executive Director Business Development and Licensing - Novartis

Dr. Kristen Albright, CEO - Prokarium

Wen Qi Ho, Therapeutics Lead - ClavystBio
Investors' Perspectives: Digital Health Trends and Investment Thesis in 2024 and Beyond
Breakout Session
- AI and Digital Health
24BC
Josh Seidenfeld, Partner and Chair, Digital Health - Cooley LLP
Quality Standards for Final Preparation of CGT Product at Point of Care (POC)
Breakout Session
- Cell and Gene Therapy and Genome Editing
31AB
Dr. Maria Amaya, Lead External Advocacy, Quality Policy and Advocacy - Genentech, A member of the Roche Group

Dr. Lesbeth Rodriguez, Director, Regulatory Affairs, Policy and Innovation - Bayer

Dr. Maria Sørensen, Specialist, RA CMC Lead - Novo Nordisk

Dr. Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)
Unlocking Success to Biotech Global Expansion: A Stepwise Game Plan for International Launch
Breakout Session
- Emerging Opportunities in Global Markets
26B
Ranu Carroll, Strategy and Transactions Life Sciences Leader - EY (Ernst & Young)
Use of AI in mRNA: The New Revolution?
Breakout Session
- Next Generation Biotherapeutics
23BC
Andy French, Director, Data & AI - CGI

Dr. Mathieu Blanchette, Director, School of Computer Science, Associate director at MILA - McGill University

Christian Barrow, Executive Director - Life Sciences - J.P. Morgan

Dr. Petrina Kamya, Vice President and Global Head of AI Platforms, Insilico Medicine - President, Insilico Medicine Canada

Andrew Giessel, Executive Director, Data Science and Artificial Intelligence - Digital at Moderna

Overcoming Development, Scale Up and Commercial Production Challenges for Novel Modalities

BioProcess BioProcess Theater

Accelerating the Globalization of Cell and Gene Therapies
Breakout Session
- Cell and Gene Therapy and Genome Editing
31AB
Jennifer Rabin, Specialist Leader - Deloitte Consulting LLP

Dirk DeNaeyer, Head of Development Operations - Galapagos

Sumant Ramachandra, CEO - Impact Bio

Dr. Shahrukh Hashmi, Faculty - Mayo Clinic
AI/ML is Transforming R&D and Business
Breakout Session
- AI and Digital Health
24BC
Dr. Maude Tessier, Chief Business Officer - Seismic Therapeutic

Karen Akinsanya, President, R&D - Therapeutics - Schrodinger, Inc.

Gary Glick, Founder and CEO - Odyssey Therapeutics

Jiye Shi, Vice President - Eli Lilly
Creative Claiming for Platforms & Products: Designing an IP Strategy to Go Global
Breakout Session
- Intellectual Property
26B
Dr. Tanis Keirstead, Partner - Mewburn Ellis

Ms. Robin Silva, Vice President of Intellectual Property - Xencor, Inc.

Dr. Malathi Lakshmikumaran, Executive Director and Practice Head - Lakshmikumaran & Sridharan

Ms. Yoon Suk SHIN, Senior Partner/Patent Attorney - Lee International IP & Law

Ms. Amy Feng, Managing Partner - Wu, Feng & Zhang
Fireside Chat

Fireside Chat with Robert A. Bradway, Chairman and Chief Executive Officer, Amgen

Fireside Chat 25ABC

Robert Bradway, Chief Executive Officer and Chairman - Amgen
Joining Forces to Accelerate Innovation in Oncology
Breakout Session
- Oncology
30ABCDE
Sponsored by:

Visali Ramanathan, Senior Director, Business Development - Genentech
NIH Support for Minority Health and Health Disparities Focused on Early-Stage Life Science Companies
Breakout Session
- Diversity‚ Equity and Inclusion
31C
Mr. Michael Banyas, Program Manager - National Institute of Minority and Health Disparities

Dr. Corine Farewell, Director UVM Innovations - University of Vermont
Partnering with CROs and their High-Value Network of Providers to Drive Speed, Cost Effectiveness and Quality in your Clinical Development

Breakout Session 23BC

Sponsored by:
Promising Advances in Neuroscience: New Molecular Targets and Biomarkers
Breakout Session
- Brain Health
26A
Dr. Hank Safferstein, Senior Advisor - UPMC Enterprises

Susanne Ahmari, Assistant Professor, Department of Psychiatry - University of Pittsburgh

Dr. Amit Etkin, Founder and Chief Executive Officer - Alto Neuroscience

Dr. Maha Radhakrishnan, Chief Medical Officer - Biogen
Strategies for Antimicrobial Access in LMICs
Breakout Session
- Infectious Disease and Vaccines
29C
Dr. Monika Schneider, Director, Global AMR Policy - Shionogi

Prof. Kevin Outterson, Executive Director - CARB-X

Mr. Yann Ferrisse, Business Development & Partner Engagement Director - GARDP Foundation
The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends
Special Program
- Business Development and Finance
32AB
David Thomas, Senior Vice President, Industry Research - Biotechnology Innovation Organization (BIO)

Building a More Sustainable Biopharma Innovation Ecosystem
Breakout Session
- Environmental Sustainability
29C
Rachel Kaufman, Head of Global Sustainability - Avantor

Joydeep Ganguly, Senior Vice President of Corporate Operations, and Chief Sustainability Officer - Gilead Sciences

Mark Steen, VP, Sustainability and Climate Initiatives - Corning
Fireside Chat

Fireside Chat with Joshua Boger, PhD, Founder and Former CEO of Vertex Pharmaceuticals; Executive Chairman, Alkeus Pharmaceuticals; Chair of Board, CervoMed

Fireside Chat 25ABC

Dr. Joshua Boger, Founder and Former CEO of Vertex Pharmaceuticals - Executive Chairman, Alkeus Pharmaceuticals; Chair of Board, CervoMed
From Incubation to Acquisition: The Growth Journey of an Early-Stage Company
Breakout Session
- Business Development and Finance
30ABCDE
Sponsored by:

Melinda Richter, Global Head - Johnson & Johnson

Matt Lorenzi, Vice President - Johnson & Johnson

Colin Farlow
Getting Personal: How the Evolving U.S. Privacy Legal Landscape Impacts Biomedical Research
Breakout Session
- AI and Digital Health
24BC
Justin Pine, Senior Director - Biotechnology Innovation Organization (BIO)

Kimberly Gold, Chief Privacy Officer - Genentech
Microgravity: A Strategic Advantage in R&D
Breakout Session
- Next Generation Biotherapeutics
23BC
Ms. Elizabeth Reynolds, Managing Director - Starburst Aerospace

Kate Rubins, Astronaut - NASA

Mr. Paul Reichert, Associate Principal Scientist - Merck

Rob Garmise, Director of Formulations Development, Exploratory Biopharmaceutics - Bristol Myers Squibb
Optimizing the Investability of Your Lead Program: Data-Driven Approaches for Pipeline Prioritization
Breakout Session
- Business Development and Finance
32AB
Dr. Drew Cutshaw, Senior Associate, Medical Officer - Pappas Capital

Mike Grey, Chairman - Plexium

Ms. Susan Lenderts, Head of Life Sciences - SAS Institute, INC

Ben Davis, Vice President, Corporate Alliances - IQVIA
Preparing for Platforms: Sponsor and Regulator Perspectives on the Platform Technology Designation (PTD)
Breakout Session
- Cell and Gene Therapy and Genome Editing
31AB
Mr. Dylan Bechtle, US Regulatory Policy Lead - Johnson & Johnson

Snehal Naik, Head of Regulatory Policy - Spark Therapeutics

Carla Vinals, Head Regulatory Strategy for Infectious Diseases - Moderna Therapeutics

Rob Berlin, Head US Regulatory Policy - GSK

Anne-Virginie Eggimann, Chief Regulatory Officer - Tessera Therapuetics
Super Session
Superconvergence: How the AI, Genetics, and Biotechnology Revolutions Will Transform our Lives, Work, and World
Super Session
- Next Generation Biotherapeutics
28ABCDE
Jamie Metzl, Founder and Chair - OneShared.World
The Bad and the Ugly: Unpacking Repercussions of the Medicaid Drug Rebate Program Rule
Breakout Session
- Business Development and Finance
29AB
Workforce, Diversity, Equity, and Inclusion at BIO: Presenting New Survey Data and Exploring Partnerships
Breakout Session
- Diversity‚ Equity and Inclusion
31C
Dr. Ted Love, Chair - BIO Board of Directors

Charlotte Jones-Burton, Founder - Women of Color in Pharma

Mark Royal, Senior Client Partner - Korn Ferry

Jane Barry-Moran, Managing Director, Programs & Research - Out Leadership

Adaptive Reuse: Biomanufacturing Enters A New Age
Breakout Session
- Environmental Sustainability
29C
Matt Gardner, Board Chairman - California Biomanufacturing Center

TJ Silvey, Director - Raymond James

Ella Woger-Nieves, CEO - Invest Puerto Rico

Gordon Zagar, President & Founder - ZCI

Ann-Stewart Patterson, Executive Vice President - CBRE
AI-Generated Invention and the Future of Bio R&D
Breakout Session
- Intellectual Property
26B
Hans Sauer, Deputy General Counsel, VP for IP - Biotechnology Innovation Organization (BIO)

Prof. Ryan Abbott, Partner - Brown, Neri, Smith & Khan, LLP

Mr. Andrei Iancu, Partner - Sullivan & Cromwell LLP

Ms. Sarah Korman, General Counsel - Isomorphic Labs
Becoming an Early Innovation Partner of Choice
Breakout Session
- Business Development and Finance
29AB
David Kane, Managing Partner - Arc Bio Communications

Helena Chaye, CEO - KaliVir

Peter Sandor, Senior Vice President, Primary Focus Lead, Primary Focus Immuno-oncology - Astellas Pharma

Olga Granaturova, CEO - PrivBio

Anna Chen, Principal - Frazier Life Sciences
Best Practices for Managing Your Biotech’s Ca$hflow
Breakout Session
- Business Development and Finance
32AB
Mr. Joel Papernik, Member - Mintz

Ms. Barbara Wood, Executive Vice President, General Counsel and Corporate Secretary - Sellas Life Sciences

Robert Van Nostrand, Board of Directors Member - Intra-Cellular Therapies

Ms. Heidi Henson, Director - Lisata Therapeutics

Mr. Robert Easton - Eastern Strategy, LLC
Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation
Breakout Session
- Brain Health
26A
Ms. Heather McKenzie, Senior Editor - BioSpace

Dr. Laxminarayan Bhat, CEO - Reviva Pharmaceuticals Inc

Dr. Amit Etkin, Founder and Chief Executive Officer - Alto Neuroscience

Daniel Karlin, Chief Medical Officer - Mind Medicine (MindMed)
Exploring the Future of Gene Delivery: A Conversation on the Direction for Next-Generation Vectors
Breakout Session
- Cell and Gene Therapy and Genome Editing
31AB
Mr. Ola Tuvesson, Chief Technology Officer - NorthX Biologics

Prof. Johan Rockberg, Professor at the Royal Institute of Technology and Director of GeneNova - Royal Institute of Technology

Dr. Peter de Haan, Founder and Chief Scientific Officer - Amarna Therapeutics BV

Dr. Amy Walker, Vice President of Research and Business Development - 4BaseBio PLC
Exploring the Uncharted: Rare Diseases, Unintended Consequences of the Inflation Reduction Act, and Demonstrating the Value of These Therapies
Breakout Session
- Orphan and Rare Disease
Future of Biopharma Innovation: Unleashing the Potential of Emerging Therapeutic Modalities in Oncology and Beyond
Breakout Session
- Next Generation Biotherapeutics
23BC
Romain Bonnot, Principal - ZS Associates

Jesper Haaning, Head of Development External Innovation - Novo Nordisk

Lucas Donigian, Executive Director, Business Development - Zymeworks Inc.

Malik Kaman, Principal - ZS Associates
Highlighting the Power of Patient Organizations: Exploring Initiatives That Drive Equitable Impact for Patients and Communities
Breakout Session
- Diversity‚ Equity and Inclusion
31C
Ms. Deepa Dahal, Co-founder and Partner - DKI Health. LLC

Ms. Mary Stutts, Chief Executive Officer - Healthcare Businesswomen's Association

Mr. Joseph Nadglowski, President and Chief Executive Officer - Obesity Action Coalition

Ms. Christine Verini, CEO - CancerCare

Ms. Sonali Chopra, Executive Director, Patient Advocacy Relations - Genentech a Member of the Roche Group
The Future of Immunology: Path to Precision Medicine
Breakout Session
- Diagnostics and Personalized Medicine
24BC
Sponsored by:

Aileen Lorenzo Pangan, Vice President & Therapeutic Area Head - Merck

Cynthia Bens, Senior Vice President - Personalized Medicine Coalition
Fireside Chat

Thinking Outside the Lab: Lessons from Nobel Laureate Carolyn Bertozzi, PhD, on Building Blockbuster Biotech Companies

Fireside Chat 25ABC

Jenny Rooke, Founder and Managing Director - Genoa Venture

Carolyn Bertozzi, Professor of Chemistry - Stanford University

Incorporating New Technologies in Development and Production, Regulatory Landscapes, and Agile Manufacturing

BioProcess BioProcess Theater

Achieving Commercial Success Through the National Institutes of Health's Intramural Research Program
Breakout Session
- Business Development and Finance
32AB
Dr. Michael Salgaller, Supervisory Specialist, National Cancer Institute Tech Transfer Center - National Institutes of Health (NIH)

Dr. Mark Rohrbaugh, Special Advisor for NIH Technology Transfer - National Institutes of Health (NIH)

Ms. Margaret Anderson, Managing Director - Deloitte Consulting LLP

Dr. Jeffery Alexander, Director, Innovation Policy - RTI International

Melissa Bonner, Chief Scientific Officer - Nvelop Therapeutics
Biotech Partnering in Stormy Seas: Key Insights on Charting a Course to Successful Deal-Making through a Choppy Market
Breakout Session
- Business Development and Finance
29AB
Kate Hillier, Partner - Cooley LLP

Daphne Zohar, Founder, CEO and Director PureTech Health (and BIO Board Member) - PureTech Health

Mrs. Barbara Kosacz, COO and General Counsel - Kronos Bio

Brian Cuneo, Senior Partner - ARCH Venture Partners

Mr. Joseph Baroldi, Executive Vice President, Chief Business Officer Ionis Pharmaceuticals - Ionis Pharmaceuticals
Breaking the Rare Disease Deadlock through Multi-Stakeholder Collaboration
Breakout Session
- Orphan and Rare Disease
26A
Dr. Niklas Blomberg, Executive Director - Innovative Health Initiative

Dr. Annette Bakker, President - Children's Tumor Foundation

Dr. Klaus Romero, Chief Executive Officer, Chief Science Officer - Critical Path Institute

Dr. Deborah Requesens, Director, JumpStart Program - Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania

Dr. Claire Skentelbery, Director General - EuropaBio
How to De-Risk Drug Development from the Earliest Stages
Breakout Session
- Business Development and Finance
23BC
Open Innovation in Life Sciences, Decades of Experiences, Time to Regroup!
Breakout Session
- Translational Research
31AB
Junjun Gao, Sr director BD&L - Bayer

Karen Chandross, Head, Strategic Initiatives and Scientific Relations N.A. • R&D North America - Sanofi

Florian Montel, Head of Open Sciences - Boehringher Ingelheim

Pamela Hill, Sr. Director, Head of Open Innovation Program - Astra Zeneca
Post-Guidance Opportunities and Challenges with Prescription Drug Use-Related Software (PDURS)
Breakout Session
- AI and Digital Health
24BC
Rob Berlin, Head US Regulatory Policy - GSK

Eva Temkin, Partner - King & Spalding

Renee Beaver, Director, Commercial Counsel - Otsuka Pharmaceutical
Running a Biotech Company: Perspectives from Women Powerbrokers
Breakout Session
- Diversity‚ Equity and Inclusion
31C
Mr. Joshua Fox, Member - Mintz

Ms. Anna Turetsky, Principal, Venture Investments - The Mark Foundation for Cancer Research

Laura Indolfi, Chief Executive Officer and Co-Founder - PanTher Therapeutics

Ms. Ridhi Tariyal, Co-Founder and CEO - NextGen Jane
Using AI/ML for Identification and Optimization of Therapeutic Molecules
Breakout Session
- AI and Digital Health
30ABCDE
Sponsored by:

Super Session

Fireside Chat with David Moore, Executive Vice President, Corporate Development, Novo Nordisk

Super Session 25ABC

David Moore, Executive Vice President, Corporate Development - Novo Nordisk

Adult Vaccination: New Vaccines, New Opportunities to Protect Public Health
Breakout Session
- Infectious Disease and Vaccines
32AB
Sponsored by:

Jannie Oosthuizen, President - Merck
Co-opting Biological Processes to Drug Cancer and Other Diseases
Breakout Session
- Oncology
26B
Mariana Mihalusova, Investor - Venrock

Dr. Larry Hamann, Co-founder/CEO - Interdict Bio

Aetna Wun Trombley, CEO - Lycia

Mr. Bernd Boidol, CEO - Proxygen

Dr. Brian Fiske, Co-founder/CSO - Mythic Therapeutics
Enhancing Clinical Trial Diversity Through a Patient-Centric, Data Driven Approach
Breakout Session
- Diversity‚ Equity and Inclusion
31C
Dr. Trevan Locke, Assistant Research Director - Duke-Margolis Institute for Health Policy

Megan Fesinmeyer, Observational Research Senior Manager - Amgen

Carla Rodriguez-Watson, Director of Research

Darryl Sleep, Head, Global Public Health - Amgen
Evolution of the IRA: A New-Year, a Potential New Administration, Yet Tackling the Same Access and Affordability Challenges
Breakout Session
- Value‚ Patient Access and Reimbursement
23BC
Mr. Stephen Morales, Senior Principal - Blue Fin Group, An IntegriChain Company

Gerry Gleeson, Head of US Market Access - Sanofi

Bill Sarraille

Albert Thigpen

Bill Roth
IPOs Are Starting to Come Back: Are You Ready?
Breakout Session
- Business Development and Finance
29AB
Mr. Rich Ramko, Partner, US Biotech Leader - EY (Ernst & Young)

Neha Krishnamohan, Chief Financial Officer and Executive Vice President of Corporate Development - Kinnate Biopharma, Inc.

Brad Wolff, Senior Managing Director |Global Advisory | Strategic Advisory | Mergers and Acquisition - Evercore

Mr. Charles Kim, Co-Chair - Global Capital Markets Practice Group - Cooley LLP
Moving from the Lab Bench to the Biotech C-Suite: Insights on Running a Founder-Led Biotech
Breakout Session
- Translational Research
31AB
Max Bayer, Staff Reporter - Fierce Biotech

Kevin Parker, CEO and Co-founder - Cartography Biosciences

Mr. Jordi Mata-Fink, CEO and Co-founder - Gate Bioscience

Mr. Trevor Martin, CEO and Co-founder - Mammoth Biosciences

Dr. Kira Poskanzer, Founder-in-Residence - Arcadia Science

Ms. Heather Bowerman, CEO & Founder - DotLab
Overcoming Systemic Data Bias via AI and Digital Health Tools: Perspectives from Providers, Pharma and Innovators
Breakout Session
- AI and Digital Health
24BC
Alexis Bortniker, Partner - Cooley LLP
Policy and Practice Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Precision Oncology
Breakout Session
- Diagnostics and Personalized Medicine
26A
Dr. Daryl Pritchard, Senior Vice President - Personalized Medicine Coalition

Jonathan Katchmore, Vice President of Commercial Diagnostic Strategy - Eli Lilly

Dr. Peter Hulick, Medical Director, Center for Personalized Medicine - NorthShore / Endeavor Health

Mr. Robert Dumanois, Director, Reimbursement Strategy - Thermo Fisher Scientific

Achieving the WHO Cervical Cancer Elimination Targets: The Value of Innovation in Achieving Pivotal Public Health Goals
Breakout Session
- Infectious Disease and Vaccines
23BC
Sponsored by:
Exploring Deal-Making Options for Your Portfolio of Assets
Breakout Session
- Business Development and Finance
29AB
Dr. Nisha Nanda, Group Vice President, Business Development - Eli Lilly

Dr. Adam Rosenthal, CEO and Founder - Star Therapeutics

Dr. Bassil Dahiyat, President and Chief Executive Officer - Xencor, Inc.

Dr. James Mutamba, Chief Business Officer - Arrakis Therapeutics

Caroline Stark Beer, Chief Business Officer - Jnana Therapeutics
Immune System Biomarkers: Can Our Antibodies Predict How We Will React to Disease and Immunotherapy?
Breakout Session
- Diagnostics and Personalized Medicine
26A
Dr. Moira Gunn, Radio Host - BiotechNation

Martin Gouldstone, Chief Executive Officer - Oncimmune

Dr. G. Scott Chandler, Global Head, Personalized Health Care (PHC) Safety - F. Hoffmann-La Roche

Dr. Ashley Orillion, Principle Scientist, AAb PAS Biomarker Platform Development Lead - Janssen Immunology

Dr. Justina Fert-Bober, Project Scientist - Cedars Sinai Medical Center
New Approaches in Radiopharmaceuticals
Breakout Session
- Oncology
31AB
Karen Tkach Tuzman, Director of Biopharma Intelligence, Head of Discovery and Preclinical Research - BioCentury

Dr. Dave Greenwald, Vice President, Business Development - Deerfield Management

Ken Song, CEO - RayzeBio

Dr. Suji Jeong, Founding Partner - The SJR Group

Jeevan Virk, Radioligand Therapy (RLT) Therapeutic Area Strategy Head - Novartis
Revolutionizing Clinical Trials: Patient Registries, Wearable Tech, and Video Capture
Breakout Session
- Clinical Trials Innovations
26B
Mrs. Allison Moore, Founder/CEO - Hereditary Neuropathy Foundation

Dr. Tina Duong, Dir, Clinical Outcomes R & D Stanford University - Stanford University

Jason Colquitt, CEO - Across Healthcare

Dr. Michelle Campbell, Associate Director, Stakeholder Engagement & Clinical Outcomes, Office of Neuroscience - FDA
Surviving Turbulence: Extending Runway and Creating Value in Healthcare and Biotech
Breakout Session
- Business Development and Finance
32AB
Cristina Ghenoiu, Investor - Mubadala Capital

Nate Chang, Operating Partner, Life Sciences - Playground Global

Rakhshita Dhar, Senior Director of Venture Investments Health - Leaps by Bayer

Andy Seid, Partner - Bioluminescence Ventures
The US Supreme Court and the End of Scientific Deference?
Breakout Session
- Regulatory Innovation
31C
Stacy Amin, Former FDA Chief Counsel - Morrison Foerster

Rob MacRae, General Counsel - GSK

Karen Day, Senior Corporate Counsel - Pfizer

Sarah Isgur, ABC News Analyst and Host, Advisory Opinions Podcast - ABC News

Jim Stansel, General Counsel - PhRMA

Julie Lovas, Deputy General Counsel - Department of Health and Human Services
Vaccinating Against Mistrust and Misinformation During an Infodemic
Breakout Session
- Infectious Disease and Vaccines
Ms. Silvia Taylor, Executive Vice President, Chief Corporate Affairs & Advocacy Officer - Novavax, Inc.

Dr. Reed Tuckson, Managing Director / Co-Founder - Tuckson Health Connections, LLC / Black Coaliition Against COVID-19

Mr. Pedro Martinez, Director, Health - UnidosUS

Sue Peschin, President and CEO - Alliance for Aging Research

Joe Smyser, CEO - The Public Good Projects (PGP)
What’s Nex-T: Innovator Roundtable on T Cell Therapies in Oncology
Breakout Session
- Oncology
24BC
Angus Liu, Senior Writer - Fierce Pharma / Fierce Biotech

Keir Loiacono, Chief Executive Officer - BlueSphere Bio

Dan Passeri, Chief Executive Officer - Cue Biopharma

David Fontana, Chief Operating and Chief Business Officer - Umoja Biopharma

Advancing the Global Regulatory Decision-Making with Public Private Partnerships
Breakout Session
- Regulatory Innovation
31C
Ms. Susan Winckler, CEO - Reagan-Udall Foundation for the FDA

Dr. Klaus Romero, Chief Executive Officer, Chief Science Officer - Critical Path Institute

Adora Ndu, Chief Regulatory Affairs Officer - BridgeBio

Carlos Garner, Senior Vice President, Global Regulatory Affairs - Eli Lilly
Approaching the Tipping Point: The Emergence of Allogeneic Cell Therapy for Oncology
Breakout Session
- Oncology
31AB
Mr. George Eastwood, Board Chair/Interim Executive Director - The Emily Whitehead Foundation

Dr. Cokey Nguyen, Chief Scientific and Technical Officer - Atara Biosciences

Ms. Abigail Jenkins, President & CEO - Gamida Cell

Dr. P.K. Morrow, Senior Vice President and Head of Oncology Therapeutic Area Unit - Takeda

Dr. Kristin Yarema, President & CEO - Poseida Therapeutics
Changing the Game: Innovation to End HIV
Breakout Session
- Infectious Disease and Vaccines
29C
Cecilia Chung, Senior Director, Strategic Initiatives and Evaluation - Transgender Law Center

Micheal Ighodaro, Co-Executive Director - Prevention Access Campaign

Jenelle Krishnamoorthy, Vice President, Head of Global Public Policy and International Affairs - Merck

Ji Ma, Head of Discovery - Brii Biosciences

Sandra Thurman, Senior Advisor to the Division of Global HIV and Tuberculosis - CDC
Competing as a Diagnostic Company in the Current Funding Environment: New Funding Models
Breakout Session
- Diagnostics and Personalized Medicine
26A
Dr. Bernard Peperstraete, CEO and Co-Founder - AcuamarkDx

Dr. Magali Haas, CEO and President - Cohen Veterans Bioscience
Inside the VC Playbook: Overcoming Obstacles in Challenging Markets for Success
Breakout Session
- Business Development and Finance
32AB
Ms. Kimberly Ha, Founder - KKH Advisors

Troy Ignelzi, Executive Advisor - Sofinnova Investments

Andrew Lam, Head of Biotech Investment - Ally Bridge Group

Enoch Kariuki, President - Endeavor Biomedicines

Sheila Gujrathi, Biotech Executive and Entrepreneur

Carol Gallagher, Independent Director
Is Oncology Still a Hot Spot for Biopharma Deals?
Breakout Session
- Oncology
24BC
Ashwin Singhania, Partner/Principal - EY (Ernst & Young)
Partnering with ARPA-H: New Opportunities and Best Practices for Engaging a Transformative R&D Funder
Breakout Session
- Business Development and Finance
29AB
Dr. Susan Monarez, Deputy Director - Advanced Research Projects Agency for Health (ARPA-H)

Dr. Jason Roos, Director, Scalable Solutions - Advanced Research Projects Agency for Health (ARPA-H)

Wade Shen, Director, Proactive Health - Advanced Research Projects Agency for Health (ARPA-H)
Regulators & DTRA Enabling DCTs
Breakout Session
- Clinical Trials Innovations
26B
Dr. Amir Kalali, Co Chair - DTRA

Jane Myles, Program Director - DTRA

Rasika Kalamegham, Head US Regulatory Policy - Genentech

Dr. Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

Loading